Background. Hepcidin is a central regulator of iron homeostasis. Increased hepcidin concentrations could cause iron-restricted erythropoiesis in chronic kidney disease (CKD)-associated anemia. This cross-sectional observational study was conducted to evaluate the association between hepcidin and CKD-associated anemia in nondialysis CKD patients. Methods. A total of 505 non-dialysis CKD patients not treated with parenteral iron were recruited, and serum hepcidin-25 levels were measured by liquid chromatography tandem mass spectrometry. Multiple linear regression analysis was used to examine the relationship between hepcidin and glomerular filtration rate (GFR) and the relationship between hemoglobin concentration and predictors including the hepcidin level. Results. The median hepcidin level among the 505 CKD patients was 15.4 ng/mL (interquartile range, 5.5-33.6 ng/mL). Although hepcidin level significantly increased according to the CKD stage, multivariate analysis did not reveal an association of GFR with the hepcidin level. Hepcidin level was a significant predictor of hemoglobin concentration after the adjustment for confounders, and a significant interaction between hepcidin and ferritin was found. After stratifying at the median ferritin level, 91 ng/mL, we found a negative association between hepcidin level and hemoglobin in the high-ferritin group. A trend toward a negative association between hepcidin level and mean corpuscular volume was observed in the high-ferritin group. Conclusions. Serum hepcidin-25 levels were negatively associated with hemoglobin concentrations in non-dialysis CKD patients with sufficient iron stores. We found that ferritin modified the association between hepcidin level and hemoglobin concentration. In addition, our results confirmed that the serum hepcidin level is not associated with GFR.
Introduction
Anemia is a major complication of chronic kidney disease (CKD) [1] . Treatment of CKD-associated anemia has been dramatically advanced by the introduction of recombinant human erythropoietin (EPO). However, CKD-associated anemia can be resistant to EPO treatment [2] . In addition to EPO deficiency, inflammatory effects of the primary disease, inflammatory effects of its complications and of its treatments, and iron-restricted erythropoiesis could be involved in this pathogenesis [3] . To achieve the optimal effect of EPO treatment, adequate iron management in patients with CKD-associated anemia is essential [4, 5] . Although serum ferritin and transferrin saturation (TSAT) are commonly used as biomarkers for iron status in CKD patients, these markers are not sensitive enough to distinguish functional iron deficiency from iron overload [2] .
Hepcidin, a 25-amino acid peptide primarily produced in the liver, is thought to be the central regulator of body iron metabolism [6] . Hepcidin controls the plasma iron concentration by inhibiting iron export by ferroportin from enterocytes and macrophages [7] . Therefore, increased hepcidin production leads to a decrease in plasma iron concentrations and to iron-restricted erythropoiesis [3] . Hepcidin expression is induced by iron loading [8] and by inflammation [9] and is suppressed by erythropoietic activity [3, 10] . Studies of humans with chronic infections and severe inflammatory disease have shown markedly increased levels of hepcidin, strongly suggesting that elevated hepcidin levels play a key role in the anemia of inflammation and reticuloendothelial blockade [9] . It is plausible that increased hepcidin concentrations may cause iron-restricted erythropoiesis also in CKD-associated anemia.
The purpose of this cross-sectional observational study was to evaluate the association of hepcidin and CKD-associated anemia in non-dialysis CKD patients. We also evaluated whether serum ferritin modified the association of hepcidin and CKD-associated anemia.
Materials and methods

Study design
We conducted the cross-sectional study from February 2007 through June 2007. Consecutive patients were recruited from the outpatient nephrology clinic at Osaka Medical General Center. Patients were eligible for this study if they were !20 years of age and had a history of CKD. Exclusion criteria included renal replacement therapy (hemodialysis, peritoneal dialysis or kidney transplant), parenteral iron therapy within 6 months preceding the period of enrollment and evidence of active bleeding or evidence of active infection. None of the patients had received EPO during the 2-week period before the study or had received blood transfusions during the 6-month period before the study. In this study, patients without missing data were extracted from these eligible patients for analyses. A total of 505 patients with Stages 1-5 CKD were enrolled. Ninety-two patients (92/505, 18%) were receiving EPO therapy (given as recombinant human EPO; 24 000 U/month). Fifteen patients (15/505, 3%) were receiving oral iron supplementation (median dose of oral iron was 100 mg daily). As controls, 63 healthy volunteers were recruited into this study from the Niigata Association of Occupational Health, Inc. This study was approved by the Institutional Review Board of Osaka General Medical Center, and all patients gave informed consent for participation in the present study in accordance with the Declaration of Helsinki.
Clinical measurements
Data on demographic characteristics and blood samples were collected at enrollment. Blood samples were immediately centrifuged, separated into aliquots and stored at À80°C for future assays. The serum levels of hepcidin-25 were quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS) by a method reported previously [11] . In brief, isotopic human synthetic hepcidin (Peptide Institute, Osaka, Japan) was mixed with each sample as an internal standard. The samples were then introduced to a PLRP-S column (5 mm, 300 Å, 150 3 2.1 mm; Varian, Inc, Palo Alto, CA) and measured by LC-MS/MS using a 4000 QTRAP LC-MS/MS System (Applied Biosystems, Foster City, CA). Concentrations of serum hepcidin were expressed in nanograms per milliliter. The intra-and interassay coefficients of variation were <6.7% and <8.8%, respectively. The lower limit of detection was 1.0 ng/mL. The median reference level of serum hepcidin in 63 healthy volunteers was 5.7 ng/ mL (interquartile range, 1.6-12.7 ng/mL).
Serum ferritin was measured by a solid phase, two-site chemiluminescent immunometric assay (Mitsubishi Chemical Medience, Tokyo, Japan). Serum C-reactive protein (CRP) was assayed using immunologic agglutination detection with latex-coupled polyclonal anti-CRP. The concentration of interleukin-6 (IL-6) was assayed by enzyme-linked immunosorbent assay (ELISA) kit (Quantikine HS; R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. Serum EPO concentrations were determined by radioimmunoassay (Mitsubishi Chemical Medience). Serum iron and total iron-binding capacity (TIBC) were measured by the colorimetric method with bathophenanthroline disulfonate as the chromogen. TSAT (%) was calculated as serum iron/TIBC. Serum creatinine was measured by enzyme assay. Estimated glomerular filtration rate (eGFR) was calculated by using the modified Modification of Diet in Renal Disease formula for Japanese: eGFR ¼ 194 3 (serum creatinine) À1.094 3 (age) À0.287 (30.739, if female) [12] . Other serum parameters were measured by using standard laboratory techniques.
Statistical analysis
Baseline characteristics were assessed with standard descriptive statistics. eGFR was examined both on a continuous scale and also categorically using the National Kidney Foundation stage system: CKD Stage 1, eGFR To examine the trend of each parameter across the CKD stages, the JonckheereTerpstra trend test and the Cochran-Armitage test were used. Quantitative variables were correlated by the Spearman rank test. To account for potential interaction by EPO administration as a confounding variable, we performed all multivariate analyses both on the series of all patients (including those using EPO) and also on the series of patients who were not treated with EPO. To examine the relationship between eGFR and the serum hepcidin level, multiple regression analyses were performed with the potential confounding variables of age, gender, ferritin, CRP and either EPO use (in the series of all patients) or EPO levels (in the series of EPOfree patients). To examine the ability of hepcidin, ferritin and TSAT to predict the hemoglobin concentration, we also performed multiple regression analyses with the potential confounding variables of age, gender, eGFR, IL-6 and either EPO use (in the series of all patients) or EPO levels (in the series of EPO-free patients). Also, given the strong relationship between hepcidin and ferritin, we specifically examined the correlation between hemoglobin concentration and the interaction between these two iron parameters. We stratified the patients at the median level of ferritin and examined whether ferritin modified the association between hepcidin level and hemoglobin concentration. To examine the relationship between mean corpuscular volume and the serum hepcidin level in EPOfree patients, multiple regression analysis was performed adjusting for age, gender, hemoglobin, eGFR, IL-6, TSAT and EPO levels. Parameters between groups were compared using the Mann-Whitney test for nonparametric continuous data, the independent t-test for parametric data and the chi-square test for categorical data. Owing to the skewed distributions, hepcidin, ferritin, CRP and IL-6 were log normalized. All results were based on analyses of the available data without any imputation procedure. P-values <0.05 were considered to be statistically significant. Most statistical analyses were performed using JMP for Windows version 5.1 (SAS Institute Inc, Cary, NC). The Jonckheere-Terpstra trend test and the Cochran-Armitage test were performed by using STATA version 10 (STATA Corp, College Station, TX). 
Results
Patient characteristics
Hepcidin levels in CKD patients
The median hepcidin level among the 505 CKD patients was 15.4 ng/mL (interquartile range, 5.5-33.8 ng/mL). Hepcidin levels as well as ferritin increased significantly as the CKD stages progressed (P-value for trend <0.001), whereas TSAT showed no significant trend with increasing CKD stages. As previous studies reported [13, 14] , log-normalized serum hepcidin was strongly correlated with the log-normalized ferritin (r ¼ 0.72, P < 0.001; Figure 1a ). The hepcidin level significantly increased according to the CKD stage, and the log-normalized hepcidin was negatively correlated with eGFR (r ¼ À0.27, P < 0.001; Figure 1b) . To examine the relationship between eGFR and the serum hepcidin level, multiple regression analyses were performed. In the multivariate models, an association of eGFR with the log-normalized hepcidin level was not observed either in the series of all patients (including EPO administration as a confounder; P ¼ 0.8) or in the series of EPO-free patients (P ¼ 1.0) ( Table 2) .
Association between hemoglobin level and iron parameters
To examine the ability of hepcidin, ferritin and TSAT to predict the hemoglobin concentration, we assessed the associations between the hemoglobin level and these iron parameters. Univariate analyses showed that the hemoglobin concentration was negatively and significantly correlated with the log-normalized hepcidin level (r ¼ À0.19, P < 0.001) and was positively correlated with TSAT (r ¼ 0.15, P ¼ 0.001) but was not correlated with log-normalized ferritin (P ¼ 0.4) (data not shown). Multiple linear regression Fig. 1 . Scatter plots of serum hepcidin-25 (ng/mL) versus (a) serum ferritin (ng/mL) and (b) eGFR (mL/min/1.73 m 2 ) among 505 patients with CKD. Log-normalized serum hepcidin was strongly correlated with lognormalized ferritin (r ¼ 0.72, P < 0.001) (a). Log-normalized hepcidin was negatively correlated with eGFR (r ¼ À0.27, P < 0.001) (b).
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analyses showed that log-normalized hepcidin was a significant predictor of hemoglobin concentration (Table 3) , both in the series of all patients as well as in the series of EPO-free patients. We assessed the effect of the interaction between log-normalized hepcidin and log-normalized ferritin, and in both series, we found a significant correlation between hemoglobin concentration and this interaction [P for interaction (log hepcidin 3 log ferritin) <0.001]. Therefore, we stratified Multivariate model included age, gender, eGFR, log IL-6, EPO level, log hepcidin, log ferritin, TSAT and the interaction term (log hepcidin 3 log ferritin). Hepcidin-25 in non-dialysis CKD patients 1079 the patients at the median ferritin level (91 ng/mL) and performed further analyses with hemoglobin concentration as the dependent variable. Patients in the high-ferritin group had significantly lower eGFR and significantly higher hepcidin and TSAT levels and significantly higher CRP and IL-6 levels, compared with patients in the low-ferritin group (Table 4) . However, there was no significant difference in hemoglobin concentration between the two groups. In the series of all patients, eight in the low-ferritin group (8/253, 3%) and seven in the highferritin group (7/252, 3%) were treated with oral iron. Univariate analysis showed that lower hemoglobin level was associated with older age, female gender, reduced eGFR, elevated IL-6 and EPO administration in each group (data not shown). Notably, the log-normalized hepcidin level was significantly negatively correlated with the hemoglobin concentration in the high-ferritin group but was not correlated in the low-ferritin group (Figure 2a and b) . In contrast, TSAT was significantly positively correlated with hemoglobin concentration in the low-ferritin group but was not correlated in the high-ferritin group (Figure 2c and d) . Only a weak correlation between log-normalized hepcidin and lognormalized CRP (r ¼ 0.15, P ¼ 0.01) and no significant correlation between log-normalized hepcidin and lognormalized IL-6 (P ¼ 0.4) was observed in the high-ferritin group, whereas there were no significant correlations between log-normalized hepcidin and these two inflammatory markers in the low-ferritin group (P ¼ 0.2 for CRP, P ¼ 1.0 for IL-6). Multiple linear regression analyses of the series of all patients and the series of EPO-free patients revealed a negative association between log-normalized hepcidin level and hemoglobin concentration in the high-ferritin groups, and in contrast, a positive association in the low-ferritin groups ( Table 5 ). As expected, in the low-ferritin groups, a lower TSAT level was significantly associated with reduced hemoglobin level. Multiple regression analysis in the EPO-free patients showed a trend for a negative association [b ¼ À1.8 (95% confidence interval (CI), À3.70 to 0.01), P ¼ 0.05] between log-normalized hepcidin level and mean corpuscular volume in the high-ferritin group and a significant positive association [b ¼ 1.4 (95% CI, 0.36-2.38), P ¼ 0.008] in the low-ferritin group (data not shown). 
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To examine whether the median ferritin level is valid as a cutoff, we performed sensitivity analyses. At a cutoff ferritin level of 100 ng/mL-the minimum ferritin level recommended by the 2006 National Kidney Foundation Disease Outcomes Quality Initiative [15] for non-dialysis CKD patients taking erythropoiesis-stimulating agents-the results were consistent with those of the median cutoff.
Discussion
To the best of our knowledge, this is the first study demonstrating that hepcidin-25 levels are negatively associated with hemoglobin concentrations in non-dialysis CKD patients with sufficient iron stores. We found that ferritin modified the association between the hepcidin level and hemoglobin concentration. In addition, although univariate analysis showed that hepcidin levels negatively correlated with eGFR, our results in multivariate analysis confirmed the results of a prior study demonstrating that the serum hepcidin level is not associated with glomerular filtration rate (GFR) after adjustment for confounders [14] . In our study, hepcidin was negatively associated with hemoglobin in non-dialysis CKD patients with sufficient iron stores. This relationship between hepcidin and hemoglobin was observed both in the series of all patients and in the series of EPO-free patients. Our results are consistent with the results of one previous study in dialysis patients [16] but inconsistent with the results of other studies in dialysis patients [17, 18] and inconsistent with studies in non-dialysis CKD patients [14, 19] . In a US study [19] , multivariate analysis showed that there was no association between serum hepcidin and hemoglobin in 48 pediatric and 32 adult non-dialysis CKD patients; in a Dutch study [14] , univariate analysis showed no such association in 83 non-dialysis CKD patients. These conflicting results may be attributable to differences in the iron status of the populations studied, differences in inflammatory state or sample size. The association of hepcidin and anemia could differ between patients with deficient iron stores and those with sufficient iron stores. Therefore, we performed analyses stratified according to the serum ferritin level and revealed details of how ferritin level modified the effect of hepcidin on anemia.
There are several reasons why hepcidin may be negatively associated with hemoglobin in non-dialysis CKD patients with sufficient iron stores. Firstly, hepcidin inhibits iron absorption from enterocytes and iron recycling from macrophages, leading to limited iron availability for erythropoiesis. High-ferritin levels normally indicate iron overload, but this does not necessarily mean sufficient bone marrow iron stores [20] . In our results, a trend for a negative association between hepcidin level and mean corpuscular volume was observed in the high-ferritin group, supporting the concept of iron-restricted erythropoiesis. Secondly, hepcidin is elevated in non-dialysis CKD patients [13, 14, 19] , as was also shown in our patients. A previous study showed that erythropoiesis activity is required in order to suppress hepcidin production [10] and in patients with reduced erythropoiesis activity, such as those with CKD, hepcidin production might not be suppressed. Thirdly, hepcidin is upregulated by inflammation [9, 21] , and CKD is an inflammatory process. However, no apparent correlation between inflammatory markers and hepcidin was observed in this population, consistent with the results of a previous study [13] . We excluded patients with active infections from the current study. Therefore, the association between hepcidin and inflammation might not have been observed in our patients. The involvement of inflammation in the association between iron availability and anemia in non-dialysis CKD patients needs to be further elucidated.
A surprising finding was that hepcidin was positively associated with hemoglobin in non-dialysis CKD patients with normal to subnormal iron stores. This relationship between hepcidin and hemoglobin was observed Hepcidin-25 in non-dialysis CKD patients 1081 both in the series of all patients and in the series of EPOfree patients. We suggest two possible explanations of why hepcidin was positively associated with hemoglobin in non-dialysis CKD patients with normal to subnormal iron stores. Firstly, the median hepcidin level among the low-ferritin group was 7.0 mg/mL (2.3-17.3 ng/mL), which may not have been sufficient to act as the main regulator of systemic iron homeostasis. Secondly, the hepcidin level may reflect absolute iron deficiency in this group. Our study confirmed a previous finding that the serum hepcidin-25 level was not associated with GFR [14] . Although several studies have demonstrated that hepcidin levels are elevated in non-dialysis CKD patients [13, 14, 19] , the association between hepcidin and GFR remains to be determined. A study from England [13] using radioimmunoassay showed that serum hepcidin level was associated with eGFR in 44 CKD patients, even after adjustment for ferritin. A US study [19] using an ELISA assay showed that the hepcidin level was inversely correlated with GFR in 32 adult CKD patients. Meanwhile, a Dutch study [14] using a mass spectrometry-based assay in 83 non-dialysis patients reported that hepcidin-25 was not associated with eGFR, but rather it was mainly associated with ferritin. Our findings in 505 non-dialysis CKD patients by using LC-MS/MS assay showed that hepcidin levels were negatively correlated with eGFR in univariate analysis (Figure 1b) . However, our results in multivariate analysis were consistent with the results from the Dutch study [14] . There are several possible explanations for the conflicting results. Firstly, there were differences in the hepcidin assays used. It is reported that hepcidin levels measured by various methods vary considerably [22] and that immunochemical assays lack the selectivity to distinguish hepcidin-25 from hepcidin-20 and -22 [23] . Secondly, the differences in sample size may have affected the results of the analyses. The analyses in previous studies were performed on samples of relatively small size. Thirdly, there may have been inherent differences in the study populations. The strength of our finding that serum hepcidin-25 was not associated with GFR is enhanced by the more specific assay and larger sample size.
This study has potential limitations. Firstly, the crosssectional nature of the present study hindered assessment of the causal relationship between hepcidin level and anemia among the CKD patients, which should be ascertained by longitudinal studies. Secondly, we did not measure hepcidin isoforms; therefore, we could not provide additional information on why different techniques may have yielded different results with respect to the association between hepcidin and GFR. Thirdly, we did not measure urinary hepcidin excretion. Fourthly, as in any observational study, we could not account for unmeasured or residual confounding.
In conclusion, hepcidin-25 levels were negatively associated with hemoglobin concentrations in non-dialysis CKD patients with sufficient iron stores. These findings need to be confirmed by longitudinal studies but may have the important clinical implication that iron stores should be taken into account when evaluating the role of hepcidin in CKDassociated anemia.
